214 related articles for article (PubMed ID: 29935731)
1. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
Bunnik EM; Aarts N; van de Vathorst S
Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
[TBL] [Abstract][Full Text] [Related]
2. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
Bunnik EM; Aarts N
BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
[TBL] [Abstract][Full Text] [Related]
3. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
Fountzilas E; Said R; Tsimberidou AM
Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
[TBL] [Abstract][Full Text] [Related]
4. Dilemmas in the compassionate supply of investigational cancer drugs.
Lewis JR; Lipworth W; Kerridge I; Doran E
Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
[TBL] [Abstract][Full Text] [Related]
5. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
[TBL] [Abstract][Full Text] [Related]
6. An ethical framework for the creation, governance and evaluation of accelerated access programs.
Pace J; Ghinea N; Kerridge I; Lipworth W
Health Policy; 2018 Sep; 122(9):984-990. PubMed ID: 30055901
[TBL] [Abstract][Full Text] [Related]
7. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians' Views and Experiences in The Netherlands.
Bunnik EM; Aarts N
J Bioeth Inq; 2021 Jul; 18(2):319-334. PubMed ID: 33590374
[TBL] [Abstract][Full Text] [Related]
8. Should patients in need be given access to experimental drugs?
Caplan AL; Bateman-House A
Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
[TBL] [Abstract][Full Text] [Related]
9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
10. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
[TBL] [Abstract][Full Text] [Related]
11. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
12. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
13. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications.
Bunnik EM; Aarts N; van de Vathorst S
J Pharm Policy Pract; 2017; 10():10. PubMed ID: 28239479
[TBL] [Abstract][Full Text] [Related]
14. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
15. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
16. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
Buckley M; O'neil C
J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
[TBL] [Abstract][Full Text] [Related]
17. Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.
Mackey TK; Schoenfeld VJ
BMC Med; 2016 Feb; 14():17. PubMed ID: 26843367
[TBL] [Abstract][Full Text] [Related]
18. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
[TBL] [Abstract][Full Text] [Related]
19. Access to 'investigational' cancer drugs: perspective of a trainee.
Kuo JC
Intern Med J; 2015 Feb; 45(2):235. PubMed ID: 25650544
[No Abstract] [Full Text] [Related]
20. An analysis of common ethical justifications for compassionate use programs for experimental drugs.
Raus K
BMC Med Ethics; 2016 Oct; 17(1):60. PubMed ID: 27756370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
